Sana Biotechnology, Inc.: research and development expense
Research and development expense for Sana Biotechnology, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Sana Biotechnology, Inc. financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 131,980,000 | USD | 2026-03-03 | 10-K · 0001193125-26-088215 |
| 2024-01-01 | 2024-12-31 | 215,673,000 | USD | 2026-03-03 | 10-K · 0001193125-26-088215 |
| 2023-01-01 | 2023-12-31 | 261,809,000 | USD | 2026-03-03 | 10-K · 0001193125-26-088215 |
| 2022-01-01 | 2022-12-31 | 285,885,000 | USD | 2025-03-17 | 10-K · 0000950170-25-040254 |
| 2021-01-01 | 2021-12-31 | 248,626,000 | USD | 2024-02-29 | 10-K · 0000950170-24-023119 |
| 2020-01-01 | 2020-12-31 | 132,944,000 | USD | 2023-03-16 | 10-K · 0001564590-23-003798 |
| 2019-01-01 | 2019-12-31 | 99,591,000 | USD | 2022-03-16 | 10-K · 0001564590-22-010539 |
Related financial histories
- Sana Biotechnology, Inc.: total assets
- Sana Biotechnology, Inc.: total liabilities
- Sana Biotechnology, Inc.: stockholders equity
- Sana Biotechnology, Inc.: cash and cash equivalents
- Sana Biotechnology, Inc.: net income or loss
- Sana Biotechnology, Inc.: operating cash flow
- Sana Biotechnology, Inc.: capital expenditure payments
- Sana Biotechnology, Inc.: financing cash flow
- Sana Biotechnology, Inc.: investing cash flow
- Sana Biotechnology, Inc.: retained earnings or deficit
- Sana Biotechnology, Inc.: basic weighted-average shares
- Sana Biotechnology, Inc.: diluted weighted-average shares
- Sana Biotechnology, Inc.: basic earnings per share
- Sana Biotechnology, Inc.: diluted earnings per share
- Sana Biotechnology, Inc.: net property, plant and equipment
- Sana Biotechnology, Inc.: share-based compensation expense
- Sana Biotechnology, Inc.: operating income or loss
- Sana Biotechnology, Inc.: current assets
- Sana Biotechnology, Inc.: current liabilities
- Sana Biotechnology, Inc.: current accounts payable
- Sana Biotechnology, Inc.: operating expenses
Inspect the source
- Entity
- Sana Biotechnology, Inc. / CIK 0001770121
- Captured
- 2026-09-21T17:26:49.530Z
- SEC response SHA-256
3afb95c874e7309a07c9f119668de86bbc70faa8ac188b06cb6886fdaeaa7e2c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001770121.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))